-
Ovarian Cancer: Symptoms, Causes, Diagnosis and Treatment(Post)
Ovarian cancer is the fourth most common cancer in women. Ovarian cancer is when the normal cells in the ovary change and grow to form a tumour. Because the ovaries are located deep
Zolbetuximab: A Breakthrough in Targeting Claudin 18.2 for Cancer Treatment(Post)Quick Facts About ZolbetuximabWhat is Zolbetuximab?Zolbetuximab is a monoclonal antibody that targets Claudin 18.2, a protein overexpressed in gastric and pancreatic cancers, enhancing t
Bococizumab: Mechanism, Clinical Applications, and Biosimilars in Research(Post)Quick Facts About BococizumabWhat is Bococizumab?Bococizumab is a monoclonal antibody that targets PCSK9, a protein involved in cholesterol regulation.How Does Bococizumab Work?It inhibi
Sample Dilution Range Calculation for Competitive ELISA kits(Post)Quick answer A competitive ELISA is running correctly when the blank (zero standard) gives the highest OD, the standard curve drops smoothly with rising concentration, and your samples land in the
Competitive vs Sandwich ELISA: Should You Subtract the Blank?(Post)Quick answer: A researcher subtracted the blank from a competitive ELISA (a Serotonin kit) and every result turned negative. In a competitive assay the signal is inversely proportional to
Platelets : The Unassuming Heroes of Blood Circulation(Post)Haematology · HaemostasisPlatelets: Formation, Structure, Activation and Clinical SignificancePlatelets are anucleate fragments shed from megakaryocytes, and they carry out primary haemostasis — adher
Growth Factors Can Cooperate to Promote Tumorigenesis(Post)Introduction Tumorigenesis, the process by which normal cells transform into cancer cells, is a multifaceted and complex event influenced by various internal and external factors. Among the
ELISA 플레이트 세척 팁(Page) One Ligand, Two Receptors, Opposite Jobs: TNFR1 vs TNFR2(Post)Blocking TNF cures rheumatoid arthritis in some patients and triggers demyelination in others. That is not a dosing problem, and it is not a patient-selection problem. It is the direct consequence of
Binding Is the Easy Part(Post)An antibody–drug conjugate is not a targeted drug. It is a delivery problem with an antibody bolted to the front of it. Binding is the easy part, and it is almost never the part that fails. What deci
Bermekimab: Unveiling the Role of Anti-CD47 in Hidradenitis Suppurativa and Atopic Dermatitis(Post)What You Need to Know About BermekimabWhat is Bermekimab?Bermekimab is a monoclonal antibody targeting the CD47 receptor, developed to modulate the immune system and improve conditions l
Narsoplimab: Targeting MASP-2 to Advance Therapies in Immune-Mediated Disorders(Post)Quick Facts About NarsoplimabWhat is Narsoplimab?Narsoplimab is a human monoclonal antibody that targets MASP-2, a key enzyme in the lectin pathway of the complement system.What is the m
The Role of Claudins in Cancer (Post)Introduction Claudins are a family of proteins that play a critical role in the formation of t
Immunophenotyping by Flow Cytometry and Cell Type Markers(Post)Immunophenotyping by Flow Cytometry Immunophenotyping is a technique used in the field of immunology and cell biology to identify and classify cells based on the specific proteins o
Vascular Endothelial Growth Factor A (VEGFA): A Cornerstone in Angiogenesis and Beyond(Post)Vascular Endothelial Growth Factor A (VEGFA) is a pivotal signaling protein involved in both vasculogenesis and angiogenesis, processes essential for the formation of blood vessels during embryoni
Melanoma: Understanding, Diagnosing, and Treating Skin Cancer(Post)Melanoma is an aggressive type of skin cancer that originates in melanocytes, the cells responsible for producing melanin, which gives skin its color. Although it is less common than othe
HMGB1 in inflammation and cancer(Post)HMGB1 Functional Overview High mobility group box 1 ( HMGB1), a member of the high-mobility group (HMG) family, was first identified in the thymus in 1973 an
サンドイッチELISA(Page)サンドイッチ ELISA プロトコル | Assay Genie | Assay Genie
Lusvertikimab: Unveiling the Potential in Immuno-Oncology(Post)What You Need to Know About LusvertikimabWhat is Lusvertikimab?Lusvertikimab is a monoclonal antibody designed to inhibit the IL-4 receptor, a key player in regulating immune responses,
Sirexatamab: Advancing CD47-Targeted Cancer Therapy and Research(Post)Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe